{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063347","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.792952+00:00","generated_at":"2026-06-08T03:17:54.982561+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Larimar completes Phase 2 50mg cohort enrollment; top-line data now Q1 2024; cash to Q1 2025","bullets":["Completed enrollment and dosing of 50 mg cohort in Phase 2 FA trial; no serious adverse events observed (blinded).","Top-line safety, PK, and frataxin data now expected in Q1 2024, refined from H1 2024.","Open-label extension trial with 25 mg daily nomlabofusp on track for Q1 2024; interim data expected Q4 2024.","Cash, equivalents, and marketable securities of $95.6M as of Sep 30, 2023; projected runway into Q1 2025.","Q3 2023 net loss $9.1M ($0.21/share) vs $8.3M ($0.37/share) in Q3 2022; R&D expenses up to $6.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063347","json":"https://secwatch.observer/filing/0000950170-23-063347.json","markdown":"https://secwatch.observer/filing/0000950170-23-063347.md","text":"https://secwatch.observer/filing/0000950170-23-063347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023063347/0000950170-23-063347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023063347/lrmr-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:17:54.982561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b7e5803e58c4bfa8ea1ec52142551f608cfa828","claim":"Larimar Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income net loss of $9.1 million, or $0.21 per share, EPS ($0.21) per share.","evidence_excerpt":"Larimar Therapeutics, Inc. (the \" Company \") announced its financial results and operational highlights for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374690/000095017023063347/0000950170-23-063347-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $9.1 million, or $0.21 per share"},{"label":"EPS","value":"($0.21) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}